GNCA
GENOCEA BIOSCIENCES INCstockOTC
InactiveJun 2, 2022
0.051USD-15.000%(-0.009)10,042,378
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
CEO
William Clark
HQ
Cambridge, Massachusetts, USA
May 22, 2019 · 1-for-8 (reverse)
GNCA Profile
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
GNCA Performance
| Period | Price | Date | Change |
|---|
